

1 ORIGINAL RESEARCH Muijzer et al

2 **Titel:** The evaluation of a web-based tool for measuring the uncorrected visual acuity and refractive
3 error in keratoconus eyes: a prospective open-label method comparison study

4 **Running title:** Web-based evaluation of visual acuity and complex refractive errors.

5 **Authors:** Marc B Muijzer^{1,2}, Janneau L J Claessens¹, Francesco Cassano², Daniel A Godefrooij¹, Yves F
6 D M Prevoo²; Robert P L Wisse^{1,2}

7 **Affiliation of authors:** ¹Utrecht Cornea Research Group, Ophthalmology Department, University
8 Medical Center Utrecht, Utrecht, Netherlands; ²Easee BV, Amsterdam, Netherlands

9 **Corresponding Authors:**

10 M.B. Muijzer

11 Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

12 Tel: +31 88 755 95 53

13 Email: m.b.muijzer@umcutrecht.nl

14 R.P.L. Wisse

15 Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

16 Tel: +31 887551683

17 Email: r.p.l.wisse@umcutrecht.nl

18 **Keywords:** digital refraction; easee; telemedicine; medical informatics; refractive error, keratoconus

19 **Financial disclosure:** MM is an employee of the UMC Utrecht & consultant for Easee BV, JC is an
20 employee of the UMC Utrecht, FC is an employee of Easee BV, DG is an employee of the UMC

21 Utrecht, YP is the CEO/founder and shareholder of Easee BV, RW is an employee of the UMC Utrecht
22 & consultant and shareholder of Easee BV. This investigator initiated study was sponsored by a grant
23 from Easee BV.

24 **Abstract:**

25 *Purpose:* To evaluate the outcome of a web-based digital assessment of visual acuity and refractive
26 error, compared to a manifest refraction assessment, in keratoconus patients with complex
27 refractive errors.

28 *Material and methods:* Keratoconus patients, aged 18 to 40, with a refractive error between -6 and
29 +4 diopters were eligible. Each participant subsequently underwent an uncorrected visual acuity and
30 a refractive assessment. Refractive error was assessed with the web-based tool (index test), an
31 autorefractor, and a manifest refraction (reference test) by an optometrist. Corrected visual acuity
32 was assessed with the web-based and manifest refractive prescription. Non-inferiority was defined
33 as the 95% limits-of-agreement (95%LoA) of the differences in spherical equivalent between the
34 index and reference test not exceeding +/- 0.5 diopters. Agreement was assessed by an intraclass
35 correlation coefficient and Bland-Altman analyses.

36 *Results:* A total of 100 eyes of 50 patients were examined. The overall mean difference of the
37 uncorrected visual acuity measured -0.01 LogMAR (95%LoA:-0.63–0.60). The variability decreased in
38 the high uncorrected visual acuity subgroup (mean difference: 0.15 LogMAR, 95%LoA:-0.25–0.55).
39 The intraclass correlation coefficient of the three refractive assessments was 0.32. The overall mean
40 difference in spherical equivalent between the index and reference test measured -0.58 diopters
41 (95%LoA:-4.49 – 3.33, P=0.008). The mean differences for myopic and hyperopic subjects were 0.09
42 diopters (P=0.675) and -2.06 diopters (P<0.001), respectively.

43 *Conclusions:* Our results show promising results in the ability of the web-based tool to remotely
44 assess visual acuity in keratoconus patients. The agreement is better in higher visual acuity ranges
45 and could provide physicians with an objective measurement to enhance teleconsultations,

46 especially relevant when access to health care is limited. The assessment of the refractive error using
47 the web-based tool was found to be inferior to the manifest refraction and deserves further training
48 of the tools algorithm.

49 **Introduction**

50 Globally, an estimated 1 billion people have a visual impairment that can be prevented or is
51 undetected and this number is expected to rise.(1,2) Main causes of visual impairment are refractive
52 errors, cataract or chronic ophthalmic conditions (e.g. macular degeneration). In an aging population,
53 the demand for eye care is increasing rapidly, which imposes a challenge for providers of eye care in
54 both developed and less-developed countries.(1,3) The acutely reduced access to healthcare during
55 the COVID-19 outbreak underlined the need for a paradigm shift in the delivery of eye care.(4)

56 To become less reliant on hospital facilities and trained professionals for monitoring eye conditions,
57 there is a growing interest in telemedicine and digital tools. In particular, promising advances have
58 been made for automatic assessment of retinal images.(5) The refractive error and visual acuity are
59 considered important clinical parameters for diagnosing and monitoring eye conditions and as such
60 various tools to remotely assess refractive errors and visual acuity are developed and clinically
61 validated.(6,7)

62 Currently, the manifest refraction – consisting of the measurement of the refractive error and the
63 visual acuity – by a trained professional is considered the gold standard.(8) Automated assessment of
64 the refractive error using an autorefractor is considered non-inferior to the manifest refraction in
65 healthy eyes.(9,10) However, the reliability of the autorefractor decreases in eyes suffering from
66 complex refractive errors (a hallmark sign of keratoconus) and it does not measure visual acuity.(11)
67 Moreover, both the manifest and automated techniques require (expensive) medical equipment
68 and/or qualified personnel and makes them unsuitable for home monitoring or use in less-developed
69 countries.

70 Recently the authors published the outcomes of the “manifest versus online refraction evaluation”-
71 trial, which reports the validation of a web-based refractive assessment in healthy adults. The tool
72 was found non-inferior to a manifest refraction performed by a trained optometrist and is accessible
73 via <https://easee.online>.(6) Notably, the tool does not require any specialized equipment – it only
74 requires a mobile phone and a computer screen – and thus can be performed in most home
75 environments. However, the authors acknowledge that the results within a healthy population are
76 not necessarily representative for individuals with a suboptimal visual performance. Therefore the
77 design of the MORE-trial included a cohort of keratoconus patients to evaluate the outcome of the
78 digital refraction tool in a population with an eye condition. Keratoconus was chosen as these
79 patients are often still able to achieve an acceptable visual acuity with a proper prescription, despite
80 their complex refractive errors, including irregular astigmatism. (11,12) Keratoconus is an uncommon
81 condition typically diagnosed in adolescents, where gradual thinning of the cornea leads to a
82 progressive ectasia and subsequent irregular astigmatism.(13,14) With its insidious onset, many early
83 patients are unaware of this diagnosis, and keratoconus patients therefore pose a challenge for any
84 assessment of refractive error.(11)


85 Here, we present the results of the keratoconus cohort of the MORE trial, a validation study of a
86 web-based tool for the assessment of visual acuity and refractive error.

87 **Material and methods:**

88 *Study Design and Recruitment*

89 Data were prospectively collected in the open-label single-center method comparison “manifest
90 versus online refraction evaluation”-trial, performed at the University Medical Center Utrecht in
91 Utrecht, the Netherlands. Participants enrolled into the study were patients who visited the
92 outpatient clinic at the University Medical Center Utrecht in Utrecht. Inclusion criteria were an
93 established diagnosis of keratoconus, a clear central cornea, and an age between 18 to 40 years.
94 Subjects were excluded if their manifest refractive error, converted to spherical equivalent, was

95 worse than -6 diopter (D; for myopia) or +4 D (for hyperopia). Furthermore, we excluded subjects
96 who had undergone corneal crosslinking 6 months prior to study participation to diminish effects of
97 corneal haze, who had diabetes, who were pregnant or lactated, or who were unable to perform the
98 a web-based refraction assessment (Figure 1). All participants provided written informed consent
99 and were enrolled in the study between January 31, 2018 and June 23, 2019.



100

101 **Figure 1.** STARD flow diagram for MORE trial. STARD flow showing participant flow through each
102 stage om the open label method comparison trial.

103 All subjects underwent 3 consecutive test designed to determine the refractive state of both eyes in
104 the following order and the subject was blinded for the outcome of all tests. First, the refractive error
105 was measured using autorefraction (Topcon RM 8800, Topcon Corporation, Japan) and corneal
106 imaging was performed using Scheimpflug tomography (Pencatam HR, Oculus GmbH, Germany).

107 Second, an optometrist performed the reference test (manifest subjective refraction). Finally, the
108 subject performed the index test using the digital refraction tool. The digital refraction tool is web-
109 based and was a custom version of the commercially available Easee refractive assessment tool,
110 specifically built for this clinical trial and is identical to the second-generation algorithm we have
111 described previously.(6) In short, a smartphone functions as a remote control by which the user
112 submits input from a distance of 3 meters to a computer screen that displays the Web-based
113 assessment. The user is presented a sequence of optotypes and astigmatism dials. Any visual acuity
114 below 1.0 (worse than 20/20) is considered to be caused by a refractive error. The web-based
115 refraction assessment is classified as a *Conformité Européenne* class 1m medical device, which is in
116 accordance with European Union Medical Device Regulation 2017/745, and the software is classified
117 as class A, which is in accordance with International Electro technical Commission standard
118 62304:2014.

119 The uncorrected distance visual acuity (UDVA) was recorded using an Early Treatment Diabetic
120 Retinopathy Study (ETDRS) visual acuity wallchart and the web-based visual acuity test. Corrected
121 distance visual acuity (CDVA) was measured using a correction based on the results of the manifest
122 and web-based refraction assessment outcome. Visual acuity was tested in accordance with
123 International Organization for Standardization standard 8596, with regard to optotypes and room
124 illumination.(15) The projected optotypes were randomized to mitigate any possible test-retest
125 effect. The study protocol did not cover the assessment of CDVA with the autorefraction result, as
126 previous research has shown a low reliability of autorefraction measurement in keratoconus
127 eyes.(11)

128 The following data were recorded for each participant/eye: age, gender, laterality, (ophthalmic)
129 medical history, Amsler-Krumeich stage (AK1: mild, AK2: moderate, AK3: severe), mean & maximum
130 keratometry, previous prescription (if known), use of spectacles or contact lenses, UDVA, CDVA, and
131 refractive outcome, including spherical and cylindrical power (in D) and axis (in degrees).

132 All procedures were performed in accordance with the Declaration of Helsinki, local and national
133 laws regarding research (i.e. the Act on Scientific Research Involving Humans), European directives
134 with respect to privacy (General Data Protection Regulation 2016/679) and medical devices (Medical
135 Device Regulation 2017/745), and the 2015 Standards for Reporting Diagnostic Accuracy Studies.(16)
136 The study protocol was approved by our institution's Ethics Review Board (METC number: 17-524),
137 and it was registered at clinicaltrials.gov (number: NCT03313921) and CCMO (number:
138 NL61478.041.17).

139 *Statistical analysis*

140 The primary study outcome was refractive error as measured using the web-based refractive
141 assessment and compared with the subjective manifest refraction and autorefraction. The signation
142 of the refractive error (+/-), spherical power, cylindrical power were converted into a spherical
143 equivalent. The agreement of the spherical equivalent of the various methods was compared using a
144 two-way mixed effect intraclass correlation coefficient (ICC) of a single measurement. In addition, the
145 difference between the measurements of the web-based and manifest assessment were compared
146 using a Fourier analysis.(17,18) Specifically, we analyzed the signation of the refractive error (+/-),
147 spherical power, cylindrical power, and axis, which were converted into power vectors.
148 Subsequently, the difference between the power vectors of the various methods was calculated as a
149 residual vector (i.e. a vector of the difference). The power vectors are non-linear in nature, which
150 precludes statistical analysis of differences between power vectors. Secondary study outcomes
151 included the UDVA and CDVA, the latter measured using the outcome of both the manifest and web-
152 based refractive assessment. A post-hoc subgroup analysis was performed for high and low vision
153 visual acuity ranges (high: ≤ 0.5 logMAR, low > 0.5 LogMAR), with a cut-off as defined by the World
154 Health Organization.(19)

155 The data was assessed for normality of the distribution. Groups were compared using the two-tailed
156 paired Student's *t* test. In addition, a multivariable generalized estimates equation (GEE) analysis of

157 the difference between the power vectors, was used to correct for bilaterality (both eyes of the same
158 patient included), keratoconus severity, age, and sex. For keratoconus severity, Amsler-Krumeich
159 stages 2 and 3 were combined, due to the low number of cases. Missing cases were not included in
160 the analysis, nor imputed, since these were not considered *missing at random*. Differences with a *P*
161 value <0.05 were considered statistically significant. The outcomes were stratified for myopia,
162 hyperopia, and keratoconus stages. The non-inferiority limit was set at 0.5 D to reflect a clinically
163 significant difference in line with literature.(20) Non-inferiority was defined as the 95% limits of
164 agreement of the difference in spherical equivalent between the web-based refractive assessment
165 and the manifest refraction not exceeding +/- 0.5. The currently applied method (comparing limits of
166 agreements rather than ICC) is more stringent and better in line with up-to-date insights in method
167 comparison studies.(21)

168 The power calculation for the MORE trial was based on an intraclass correlation for the 3 different
169 refraction methods, using the following formula in R: Sample size
170 ($p=0.70, p_0=0, k=3, \alpha=(0.05/12), \text{tails}=2, \text{power}=0.80, \text{by}="p", \text{step}=0.025$). Data were analyzed
171 using SPSS version 25.0 (IBM, Armonk, New York, USA) and R statistical software version 4.0.3 (CRAN,
172 Vienna, Austria). For the Bland-Altman analysis the "BlandAltmanLeh" (version 0.3.1) package was
173 used.

174 **Results:**

175 A total of 100 eyes from 50 keratoconus patients were included in the study, no subjects were
176 excluded. The clinical characteristics of the study population are summarized in Table 1 and all
177 relevant variables are stratified for Amsler-Krumeich keratoconus stage.(13) The majority of the
178 participants was male (78%, n=39), and used visual aids to correct their refractive error (78%, n=39).
179 Both results were expected; keratoconus is more prevalent in males and the hallmark cone shape in
180 keratoconus induces myopia and (irregular) astigmatism.(13) A total of 23 underwent corneal
181 crosslinking (n= 37 eyes), all resolved without sequelae. A total of 9 subjects reported ocular

182 complaints at the time of the measurement; all subjects reported blurred vision. No adverse events
 183 or complications were recorded during the trial. The refractive error and visual acuity data was
 184 missing in 13 subjects (11 myopic and 2 hyperopic) because of a technical error in the web-based
 185 refractive assessment.

Table 1. Clinical characteristics of the study population (100 eyes of 50 patients)				
Age (years), mean ± SD	25.6 ± 5.4			
Sex (male), n (%)	39 (78)			
Current use of visual aids, n (%)	38 (78)			
Spectacles, n (%)	28 (56)			
Contact lenses, n (%)	17 (34)			
Ocular complaints, n (%)	9 (18)			
Medication use, n (%)	10 (20)			
Previous surgical treatment, n (%)	24 (48)			
Distribution of refractive errors and keratoconus severity classification^a				
	Total (n=100)	Mild keratoconus AK stage 1 (n=84)	Moderate keratoconus AK stage 2 (n=13)	Severe keratoconus AK stage 3 (n=3)
Mean keratometry, mean ± SD	45.66 ±2.90	45.27 ±2.79	47.46 ±1.75	48.63 ±5.37
Maximum keratometry, mean ± SD	52.55 ±6.39	52.08 ±6.30	54.50 ±4.48	57.33 ±13.68
Refractive error ¹	100	84	13	3
Hyperopia, n	29	23	5	1
Emmetropia, n	5	5	0	0
Mild myopia, n	44	40	4	0
Severe myopia	22	16	4	2


186 Abbreviations: AK; Amsler-Krumeich stage, SD; standard deviation

187 ^a Mild myopia was defined as refractive error of –3 diopter or less; severe myopia was defined as refractive
 188 error worse than –3 diopter. Refractive error was determined on the basis of the spherical equivalent of the
 189 manifest refraction value, (reference test), and is reported for both eyes separately. The distribution of
 190 refractive errors was not significantly different between the classifications ($P=0.30$).

191 *Intraclass Correlation Coefficients*

192 The concordance of the refractive error among the three methods was assessed using the ICC of the
 193 spherical equivalent. The overall ICC of all 3 measurements was 0.32 (95% CI 0.19 - 0.46). The ICC for
 194 the manifest refraction and web-based refractive assessment was overall 0.36 (95% CI 0.22 - 0.53)
 195 and for the mild keratoconus subgroup 0.48 (95% CI 0.29 - 0.64). All eyes were included in the ICC
 196 because of the asymmetrical manifestation of keratoconus. ICC calculations for either all right or left
 197 eyes separately did not lead to new insights.

199 UDVA was measured using the digital index test and with an ETDRS visual acuity wall chart as
 200 reference. Mean UDVA measured digitally was logMAR 0.57±0.39 (Snellen 0.38±0.33), and with the
 201 ETDRS wall chart logMAR 0.58±0.52 (Snellen 0.46±0.40). The mean difference between the
 202 measurements was considered small and non-significant (-0.01 LogMAR, P=0.76). There was a
 203 considerable distribution in measurement differences (95% LoA: -0.63 – 0.60). In the high visual
 204 acuity subgroup (<=0.5 LogMAR) this variability decreased (mean difference: 0.15 LogMAR, 95% LoA:
 205 -0.25 – 0.55). In the low visual acuity subgroup the mean difference between both measurements
 206 was -0.20 LogMAR(95% LoA: -0.82 – 0.41). Figure 2 depicts the correlation of the web-based visual
 207 acuity assessment compared with the ETDRS measurement in a Bland-Altman plot. The visual acuity
 208 assessments do not agree equally through the range of measurements. As can be observed in the
 209 high visual acuity subgroup, the majority of the measures show little difference and the mean
 210 difference is mostly attributed to outliers. In the lower visual acuity ranges, the measurements
 211 appear to be much more variable.



213 **Figure 2.** A Bland-Altman plot displaying the differences in logarithmic minimum angle of resolution
214 (LogMAR) between the web-based uncorrected distance visual acuity assessment (index test) and the
215 ETDRS uncorrected distance visual acuity measurement (reference test). The differences between
216 the reference test and index test shown on the Y-axis are expressed as the difference of the web-
217 based uncorrected distance visual acuity assessment outcome minus the ETDRS uncorrected distance
218 visual acuity outcome. The x-axis shows the mean visual acuity in LogMAR of the two assessments,
219 where a more negative value represents a higher visual acuity. The outcome is stratified for a high
220 visual acuity subgroup (uncorrected distance visual acuity ≤ 0.5 LogMAR) highlighted with a red
221 circle.


222

223 *Overall outcome of the web-based refraction assessment*

224 Assessments of refractive error are reported stratified for myopia and hyperopia (see Table 2).
225 Detailed outcomes per keratoconus stage are found in the supplementary tables (supplementary
226 Table 1 and 2). Overall, the spherical equivalent of the refractive error measured using the manifest
227 refraction and the web-based refraction assessment differed significantly for both myopic (0.09D)
228 and hyperopic subjects (-2.06D). Albeit the relatively small mean difference, the 95% LoA of the
229 difference of the spherical equivalent extended beyond the *a priori* set non-inferiority limit of 0.5 D
230 in both myopic subjects (95% LoA -3.28 – 3.47) and hyperopic subjects (95% LoA -5.52 – 1.39). When
231 transposed into power vectors these differences measure -1.08D for myopic subjects and -0.69D for
232 hyperopic subjects (Table 2, top row). Figure 3 depicts the correlation of the web-based refraction
233 assessment compared with the reference test. The visualization shows a wide distribution of
234 differences between the assessments overall. However, within the emmetropic/myopic refractive
235 error group the agreement between the methods improves in the low refractive error ranges.
236 Furthermore, it can be observed that the web-based refractive assessment yields a more hyperopic
237 outcome in higher myopes (i.e. undercorrected) and a more myopic refractive outcome in low

238 myopics (i.e. overcorrected). When outcomes of the refractive assessment are broken down per
 239 keratoconus stage, the more advanced keratoconus cases (AK stage 2 and 3) show an increased
 240 difference between the index and reference test (supplementary data Table 1 and 2).

241 We performed a multivariable Generalized Estimating Equations (GEE) analysis to correct for the
 242 inclusion of two eyes of one patient, age, sex, and keratoconus severity (supplementary Table 3). As
 243 expected the Amsler-Krumeich stage >1 (B=1.167, P=0.027) had a significant effect on the power
 244 vector of the manifest refraction, indicating the refractive error increases with keratoconus severity.
 245 The web-based refraction did not identify this increase in power vector. Stratification of outcomes
 246 for myopia and hyperopia revealed no new insights.



248 **Figure 3.** A Bland-Altman plot displaying the differences in refractive error between the web-based
 249 refractive assessment (index test) and the manifest refraction (reference test). The difference
 250 between the reference and index test shown on the Y-axis is expressed as the difference of the web-
 251 based refractive assessment outcome compared to the manifest refraction. The x-axis shows the

252 mean spherical equivalent of the two assessments. Myopia and hyperopia were based on the
253 spherical equivalent of the manifest refraction.

254

255 The algorithm of the digital refraction was not always able to correctly determine the participant's
256 refractive error as either myopia (-) or hyperopia (+). In a total of 21 cases (21%) the signation between
257 the index test and the reference test differed, with an average absolute difference in refractive error
258 of -2.38 ± 1.96 . Determining the correct signation in hyperopic subject proved challenging: in 20 of 27
259 (74%) of hyperopic subjects the signation switched between the index and reference test. Strikingly,
260 only one myopic case was incorrectly identified by the online test (98% success). Naturally, this has
261 profound effect on the attained corrected distance visual acuities with the web-based prescription.

Table 2. Measured refractive error and visual acuity										
Refractive error and visual acuity	Emmetropic and myopic subject					Hyperopic participants				
	Web-based refraction ^a (n=60)	Manifest Refraction ^a (n=71)	Difference ^{b,c}	95% CI	P-value ^d	Web-based refraction ^a (n=27)	Manifest refraction ^a (n=29)	Difference ^{b,c}	95% CI	P-value ^d
Power vector ^{e,f} (D)	2.34 ±1.02	2.69 ±1.74	-1.08	-1.41 – -0.74	N.A.	1.35 ±0.68	2.02 ±1.04	-0.69	-0.92 – -0.46	N.A.
Power vector J0 ^f (X)	-0.08 ±0.54	-0.61 ±1.17	-1.16	-1.41 – -0.90	N.A.	-0.08 ±0.26	-1.27 ±1.01	-1.47	-2.00 – -0.93	N.A.
Power vector J45 ^f (Y)	0.05 ±0.62	0.02 ±0.86	-0.72	-0.91 – -0.53	N.A.	-0.04 ±0.23	-0.16 ±1.00	-0.98	-1.41 – -0.54	N.A.
SEQ (D)	-1.96 ±1.20	-2.05 ±1.76	0.09	-0.35 – 0.54	0.675	-1.02 ±1.40	1.04 ±0.83	-2.06	-2.76 – -1.37	<0.001
Sphere	-1.53 ±1.15	-0.87 ±1.79	-0.76	-1.23 – 0.28	N.A.	-0.59 ±1.39	2.68 ±1.45	-3.28	-4.22 – 2.33	N.A.
Cylinder	-1.00 ±1.02	-2.44 ±1.84	1.58	1.06 – 2.12	N.A.	-0.93 ±0.91	-3.14 ±1.86	2.21	1.39 – 3.03	N.A.
Axis	83 ±45	92 ±45	-9	-20 - 1	N.A.	81 ±64	93 ±20	-53	-143 - 37	N.A.
CDVA LogMAR	0.23 ±0.35	0.00 ±0.12	0.26	0.15 – 0.37	<0.001	0.19 ±0.27	0.01 ±0.13	0.17	0.08 – 0.27	0.001
CDVA Snellen	0.72 ±0.37	1.03 ±0.28	0.38	-0.51 - -0.27	N.A.	0.73 ±0.32	1.01 ±0.26	-0.27	-0.39 - -0.16	N.A.

262 Abbreviations: CDVA: corrected distance visual acuity, CI: confidence interval, D: diopter, , N.A.: not assessed, SEQ: spherical equivalent, logMAR: logarithm of the minimum angle of resolution for visual
263 acuity

264 ^aUnless otherwise specified, reported as mean ±SD.

265 ^bUnless otherwise specified, reported as mean difference (web-based minus manifest assessment).

266 ^cDifferences are based on the 54 and 26 cases with both manifest and digital refraction data available, leading to small deviations when subtracting the reported mean data in the table.

267 ^dPaired-sample Student t test was performed for predefined primary and secondary outcome parameters only.

268 ^eSpherical and cylindrical power and axes were translated into vectors using Fourier analysis and the difference is calculated as a power vector of the difference between the power vectors.

269 ^fThe difference between power vectors and the vector specific parameters are calculated as a residual vector and is non-linear.

270 *Corrected visual acuity measurement using the web-based refraction measurement*

271 The overall achieved corrected distance visual acuity was significantly lower with the digital
272 prescription (0.22 ± 0.32 logMAR) vs. the reference test (-0.01 ± 0.13 LogMAR, $P < 0.001$). For myopic
273 cases the mean difference in CDVA was 0.23 logMAR (95%CI -0.37 to -0.15; Snellen 0.31 95%CI 0.27
274 to 0.51). For hyperopic cases these outcomes were comparable (-0.22 logMAR; 95%CI -0.27 to -0.08;
275 Snellen 0.31 95%CI 0.16 to 0.39). This underlines that the variation in refractive outcomes translate
276 to visual acuity outcomes on average 3 lines less read on a visual acuity chart.

277 In 51 eyes (n=26 subjects) the CDVA was not assessed with the prescription of the web-based
278 refractive error assessment. In 13 eyes the web-based refraction assessment did not yield an
279 outcome because of the previous mentioned technical errors. In 19 consecutive assessed patients
280 the CDVA was not assessed due to an incorrect instruction of a member of the research team. We
281 identified no other relevant associations, and considered these data missing at random.

282 **Discussion**

283 In this clinical method comparison study we compared a web-based tool for measuring refractive
284 errors with a manifest refraction, the current gold standard, in keratoconus patients. The relevance
285 of delivering remote eye care has been illustrated during the COVID-19 outbreak.(4) With an acute
286 reduction in access to care during this period, the most relevant finding of our studies is that visual
287 acuity can be assessed using a web-based exam, in healthy subjects as well as in individuals with a
288 complex refractive error and an ophthalmic condition.(6) In the high visual acuity group the
289 agreement of the measurements is high. It should be noted that repeated visual acuity assessments
290 always demonstrate variability due to measurement variation. Cross-sectional studies on
291 repeatability of clinical logMAR wallcharts revealed 95% limits of agreements of ± 0.15 logMAR.(21)
292 When looking at the visualized differences between the web-based test and the reference test we
293 consider the agreement to be clinically acceptable. Notwithstanding, the spread in the outcomes of
294 the web-based refraction assessment exceeded the predefined non-inferiority margins (of $< 0.5D$),

295 and poorly correlated with the gold standard manifest refraction (for myopia 95% LoA: -3.28 – 3.47,
296 and for hyperopia 95% LoA: -5.52 – 1.39; ICC: 0.36). As a result, the attained CDVA with the
297 prescription of the web-based tool was significantly lower than the traditional manifest refraction
298 (logMAR 0.23 vs. 0.00, $P < 0.001$). It should be noted that the refractive assessments do not agree
299 equally throughout the range of measurements. The agreement appears to improve in the low
300 myopic refractive error range, suggesting a better performance of the web-based refractive
301 assessment in this range. Furthermore, we observed that the web-based refractive assessment
302 undercorrected higher myopics and overcorrected lower myopics. Both effects might be mitigated by
303 a judicial re-calibration of the algorithm of the online test.

304 The performance of the web-based refractive assessment in this study population can be explained
305 by the design of the algorithm. The algorithm translates the measured visual acuity in a refractive
306 error. Next, the astigmatic refractive error is assessed and the spherical and cylindrical components
307 are determined. The algorithm assumes that the loss of visual acuity is proportional to the increase in
308 refractive error, and that all vision loss is caused by a refractive error. These two assumptions
309 obviously do not necessarily stand in eyes with an ophthalmic condition.

310 The signation (either + or -) is assessed by a red/green test, and by asking the participant questions
311 on the experience of their visual function (do you have problems reading, do you recognize faces
312 from afar etc.). These questions appear to suffice in a healthy population (98% success)(6), but are
313 not considerable reliable in this population (80% success): keratoconus patients often have problems
314 with both near and far tasks, and the questions have not always been discriminative. This effect is
315 more pronounced in hyperopic refractive errors and could be mitigated by feeding the algorithm
316 more data than was available in the clinical trial, in particular data on any previous prescriptions. This
317 is the case in the commercially available exam: an optometrist assesses any existing prescription and
318 validates the findings that are produced by the algorithm. The here employed clinical trial algorithm
319 functioned completely independent.

320 Several considerations of the study deserve attention. No randomization of the test order was
321 performed, which could have impacted our results as subject may become tired during the
322 assessments. However, because of the fixed test order, this should have impacted all subject
323 similarly. The learning or training effect is considered negligible since the three refractive assessment
324 methods are very different and randomized optotypes were used for assessment of the visual acuity.
325 Observer bias cannot be excluded as the observer had access to all test results. A consideration
326 should be made regarding the missing data. The primary outcome – refractive error- was missing in
327 13 eyes because of technical errors. The number of technical errors was evidently higher when
328 compared to the healthy study population previously described (6/200 eyes).(6) The data were
329 particularly missing in cases with higher refractive errors and lower visual acuities (i.e. the more
330 severe cases), suggesting these cases are not missing at random. Apparently, the complex refractive
331 errors pose a challenge for the algorithm. This may have impacted the study power. The missing data
332 are considered to have little impact on our conclusions, since we already concluded that the
333 algorithm’s performance is poor in this group. Lastly, the participants were young (25.6 years on
334 average) and presumably digital natives: the uptake of these novel tools in an elderly population
335 warrants a design tailored to their needs and digital aptitude.

336 The digital refraction fits into the current trend of health care digitalization as health care demand is
337 increasing.(22) Importantly, this is expected to increase because of an aging population, whereas
338 health care budgets are capped, and countries experience a shrinking workforce.(23–25) In addition,
339 telemedicine has the ability to alleviate the urgent challenges our health care systems are currently
340 facing. Several studies have shown the potential of digital eye care tools and the use of digital tools
341 for diagnosis and monitoring of patients.(7,26–29) In particular, the PEEK vision tool developed by
342 Bastawrous et al, provided health care professionals with accurate and vital information regarding a
343 person’s ocular health status, and improved eye health in a rural African community.(7)
344 Notwithstanding, our results show that validation is of utmost importance preceding clinical

345 implementation of these tools and new iterations are needed to further improve the accuracy of the
346 here studied web-based assessment tool.

347 **Conclusions**

348 The web-based digital eye exam is able to deliver estimates of visual acuity, achieved independently
349 and remotely by the patient. Contrary to the previously published results with healthy volunteers,
350 the assessment of refractive error posed too big a challenge for the digital algorithm and its
351 prescription resulted in a significantly poorer visual performance. These data will aid in a better
352 training and calibration of the web-based test, with the potential to better identify outlier
353 measurements and increase overall test reliability. A web-based exam should not be considered a
354 replacement for a comprehensive manual examination by an eye care professional. Notwithstanding,
355 the outcome of the digital eye exam can provide doctors with an objective measurement of visual
356 function which enhances a teleconsultation. The latter is especially important in times or areas with
357 limited access to health care.

358 **Abbreviations:**

359 **AK:** Amsler Krumeich

360 **CDVA:** Corrected distance visual acuity

361 **CI:** confidence interval

362 **D:** diopter

363 **ETDRS:** Early Treatment Diabetic Retinopathy Study

364 **LoA:** limits of agreement

365 **LogMAR:** logarithm of the minimum angle of resolution

366 **GEE:** generalized estimates equation

367 **UDVA:** uncorrected distance visual acuity

368 **ICC:** intraclass correlation coefficient

369 **Acknowledgements:**

370 The authors are grateful to Emma van Hamersveld BSc, for her assistance in composing the
371 regulatory and ethical board review documentation, and to Nienke Soeters PhD, Veerle Berkhof BSc
372 and Timon Legemaat BSc for their assistance in acquiring the data.

373 **Financial disclosure:** MM is an employee of the UMC Utrecht & consultant for Easee BV, JC is an
374 employee of the UMC Utrecht, FC is an employee of Easee BV, DG is an employee of the UMC
375 Utrecht, YP is the CEO/founder and shareholder of Easee BV, RW is an employee of the UMC Utrecht
376 & consultant and shareholder of Easee BV. This investigator initiated study was sponsored by a grant
377 from Easee BV.

378 **References**

- 379 1. Bourne RRA, Flaxman SR, Braithwaite T, Cicinelli M V., Das A, Jonas JB, et al. Magnitude,
380 temporal trends, and projections of the global prevalence of blindness and distance and near
381 vision impairment: a systematic review and meta-analysis. *Lancet Glob Heal.* 2017;5(9):e888–
382 97.
- 383 2. World Health Organisation. Global Data on visual impairment. 2010.
- 384 3. Németh J, Tóth G, Resnikoff S, de Faber JT. Preventing blindness and visual impairment in
385 Europe: What do we have to do? *Eur J Ophthalmol.* 2019;29(2):129–32.
- 386 4. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based
387 mitigation measures influence the course of the COVID-19 epidemic? *Lancet.*
388 2020;395(10228):931–4.

- 389 5. De Fauw J, Ledsam JR, Romera-Paredes B, Nikolov S, Tomasev N, Blackwell S, et al. Clinically
390 applicable deep learning for diagnosis and referral in retinal disease. *Nat Med*.
391 2018;24(9):1342–50.
- 392 6. Wisse RPL, Muijzer MB, Cassano F, Godefrooij DA, Prevoo YFDM, Soeters N. Validation of an
393 independent web-based tool for measuring visual acuity and refractive error via the MORE
394 (Manifest Versus Online Refractive Evaluation) trial: Prospective open-label noninferiority
395 clinical trial. *J Med Internet Res*. 2019;21(11):1–13.
- 396 7. Bastawrous A, Rono HK, Livingstone IAT, Weiss HA, Jordan S, Kuper H, et al. Development and
397 validation of a smartphone-based visual acuity test (peek acuity) for clinical practice and
398 Community-Based Fieldwork. *JAMA Ophthalmol*. 2015;133(8):930–7.
- 399 8. Elliott DB. What is the appropriate gold standard test for refractive error? *Ophthalmic Physiol*
400 *Opt*. 2017;37(2):115–7.
- 401 9. Pesudovs K, Weisinger HS. A comparison of autorefractor performance. *Optom Vis Sci*.
402 2004;81(7):554–8.
- 403 10. Bullimore MA, Fusaro RE, Adams CW. The Repeatability of automated and clinican refraction.
404 Vol. 75, *Optometry and vision science*. 1998. p. 617–22.
- 405 11. Soeters N, Muijzer MB, Molenaar J, Godefrooij DA, Wisse RPL. Autorefraction Versus Manifest
406 Refraction in Patients With Keratoconus. *J Refract Surg*. 2018;34(1):30–4.
- 407 12. Wisse RPL, Gadiot S, Soeters N, Godefrooij DA, Imhof SM, van der Lelij A. Higher-order
408 aberrations 1 year after corneal collagen crosslinking for keratoconus and their independent
409 effect on visual acuity. *J Cataract Refract Surg*. 2016 Jul;42(7):1046–52.
- 410 13. Rabinowitz YS. Keratoconus. *Surv Ophthalmol*. 1998;42(4):297–319.
- 411 14. Godefrooij DA, de Wit GA, Uiterwaal CS, Imhof SM, Wisse RPL. Age-specific Incidence and

- 412 Prevalence of Keratoconus: A Nationwide Registration Study. *Am J Ophthalmol.*
413 2017;175:169–72.
- 414 15. International Organization for Standardization. *Ophthalmic optics -- Visual acuity testing --*
415 Standard and clinical optotypes and their presentation. ISO 8596:2017. 2017.
- 416 16. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an
417 updated list of essential items for reporting diagnostic accuracy studies. *BMJ.* 2015
418 Oct;351:h5527.
- 419 17. Raasch T. Clinical refraction in Three-Dimensional Dioptic Space Revisited. *Optom Vis Sci.*
420 1997;74(6):376–80.
- 421 18. Thibos LN, Wheeler W, Horner D. Power vectors: an application of Fourier analysis to the
422 description and statistical analysis of refractive error. *Optom Vis Sci.* 1997;74(6):367–75.
- 423 19. World Health Organisation. *Global Initiative for the Elimination of Avoidable Blindness : action*
424 plan 2006-2011. Geneva; 2007.
- 425 20. Goss DA, Grosvenor T. Reliability of refraction--a literature review. *J Am Optom Assoc.* 1996
426 Oct;67(10):619–30.
- 427 21. Bunce C, Czanner G, Moschandreas J, Stratton IM, Doré C, Freemantle N. *Ophthalmic statistics*
428 note 14: method agreement studies in ophthalmology: the intraclass correlation coefficient?
429 *Br J Ophthalmol.* 2020 Aug 1;104(8):1033 LP – 1035.
- 430 22. Ray Dorsey E, Topol EJ. State of telehealth. *N Engl J Med.* 2016;375(2):154–61.
- 431 23. Sheiner L. The determinants of the macroeconomic implications of aging. *Am Econ Rev.*
432 2014;104(5):218–23.
- 433 24. Mongan JJ, Ferris TG, Lee TH. Options for slowing the growth of health care costs. *N Engl J*

- 434 Med. 2008;358(14):1509.
- 435 25. Turner D, Giorno C, Serres A De, Vourc'h A, Richardson P. The macroeconomic implications of
436 ageing in a global context. 1998. 130 p.
- 437 26. Lord K, Shah VA, Krishna R. The eye handbook: A mobile App in Ophthalmic Medicine. Mo
438 Med. 2013;110(1):49–51.
- 439 27. Phung L, Gregori NZ, Ortiz A, Shi W, Schiffman JC. Reproducibility and comparison of visual
440 acuity obtained with Sightbook mobile application to near card and Snellen chart. Retina.
441 2016;36(5):1009–20.
- 442 28. Ciuffreda KJ, Rosenfield M. Evaluation of the SVOne: A handheld, smartphone-based
443 autorefractor. Optom Vis Sci. 2015;92(12):1133–9.
- 444 29. Pamplona VF, Mohan A, Oliveira MM, Raskar R. NETRA: Interactive display for estimating
445 refractive errors and focal range. ACM SIGGRAPH 2010 Pap SIGGRAPH 2010. 2010;29(4).
- 446
- 447

